Release Date: 12-Jul-2024
The combination of bispecific antibodies with radiation therapy or chemoradiation presents a promising strategy in cancer treatment, capitalizing on synergistic effects to enhance tumor control and improve patient outcomes. Bispecific antibodies, with their ability to engage the immune system and target tumor cells simultaneously, augment the antitumor response induced by radiation therapy or chemoradiation. This combination approach has the potential to overcome tumor resistance, enhance tumor cell killing, and stimulate synthetic immune responses against cancer. Clinical investigations exploring this synergy show encouraging outcomes, underscoring the potential of bispecific antibodies in optimizing the therapeutic efficacy of radiation-based treatment modalities in cancer treatment.